UNASSIGNED: High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/ @entity706 . We evaluate the long-term outcome of @entity1 with relapsed or @entity706 treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/ @entity706 @entity1 treated with a program of @entity4349 -based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of @entity1 had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of @entity1 progressed. After rituximab, @entity786 , @entity1891 , @entity229 (R-COP), CR was obtained in 60% and PR in 35%; 118 @entity1 successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative @entity1 was @entity588 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory @entity1 with high dose autologous transplantation of in vivo purged progenitor cells. Am. J. Hematol. 90:230-234, 2015.    2014 Wiley Periodicals, Inc.

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/ XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity588 :: ('596', 'Gene') :: ['bcl-2'] @entity706 :: ('MESH:D008223', 'Disease') :: ['refractory follicular lymphoma'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']
@entity706 :: (MESH:D008223,Disease) :: ['refractory follicular lymphoma']
